WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (Nasdaq: EGRX) today announced its financial results for the three months ended March 31, 2019. Highlights of, and subsequent to, the first quarter of 2019 include:
Business and Recent Highlights:
-
Completed a successful study to evaluate the neuroprotective effects
of RYANODEX® (dantrolene sodium) for the treatment of nerve
agent exposure:
- Conducted in collaboration with the United States Army Medical Research Institute of Chemical Defense (USAMRICD), the nation's leading science and technology laboratory in the area of medical chemical countermeasures research and development;
- The Company plans to meet with the U.S. Food and Drug Administration (FDA) as soon as possible;
- Announced a revised licensing agreement for BENDEKA that extends the term of the agreement until the product is no longer sold and increases Eagle’s royalty rate from 25% to 30% in October 2019 and by 1% annually until it reaches 32%;
- The FDA issued a decision in favor of Eagle regarding the scope of BENDEKA’s Orphan Drug Exclusivity (ODE), further protecting the longevity of the BENDEKA franchise; and
- The Centers for Medicare and Medicaid Services (CMS) established a unique, product specific, billing code (J-code: J9036) effective July 1, 2019, for BELRAPZO, the brand name under which Eagle’s currently marketed 500mL infusion bendamustine solution will be sold beginning June 3, 2019.
Financial Highlights:
- Total revenue for the first quarter of 2019 was $49.8 million, compared to $46.6 million in the first quarter of 2018;
- Q1 2019 bendamustine hydrochloride 500ml solution (“Big Bag” or “BELRAPZO”) product sales were $3.2 million;
- Q1 2019 RYANODEX product sales were $4.0 million, compared to $4.4 million in Q1 2018;
- Q1 2019 net income was $9.0 million, or $0.64 per basic and $0.62 per diluted share, compared to net income of $2.6 million, or $0.18 per basic and $0.17 per diluted share in Q1 2018;
- Q1 2019 adjusted non-GAAP net income was $14.6 million, or $1.05 per basic and $1.01 per diluted share, compared to adjusted non-GAAP net income of $8.2 million, or $0.55 per basic and $0.53 per diluted share in Q1 2018; and
- Cash and cash equivalents were $102.1 million, net accounts receivable was $63.9 million, and debt was $42.5 million as of March 31, 2019.
“This is an exciting time at Eagle as we continue to position the Company for growth. We have solidified our bendamustine franchise by securing marketing exclusivity for BENDEKA and effectively preventing generic competition through the end of 2022, revising our licensing agreement for BENDEKA to extend the term of the agreement well beyond 2025 and increase our royalty rate, and launching BELRAPZO, our 500mL infusion bendamustine product, which will have its own unique J-code effective July 1st of this year. Combined, these efforts now give us the most certitude for our bendamustine portfolio since launch and should provide a very strong base of earnings upon which we can continue to build to further grow the Company,” stated Scott Tarriff, Chief Executive Officer of Eagle Pharmaceuticals.
“With bendamustine as a solid base for many years to come, we are excited about our pipeline. Today’s news about RYANODEX for nerve agent exposure is an important step in diversifying our product line and building growth,” concluded Tarriff.
First Quarter 2019 Financial Results
Total revenue for the three months ended March 31, 2019 was $49.8 million, as compared to $46.6 million for the three months ended March 31, 2018. We recorded $9.0 million in revenue during the first quarter of 2019 upon execution of an agreement to terminate Teva’s obligation to pay future milestones and royalties on BENDEKA sales outside of the U.S.
Royalty revenue was $26.3 million in the first quarter of 2019, compared to $35.8 million in the first quarter of 2018. BENDEKA royalties were $26.0 million in the first quarter of 2019, compared to $34.0 million in the first quarter of 2018. A summary of total revenue is outlined below:
| Three Months Ended March 31, | |||||||
| 2019 | 2018 | ||||||
| (unaudited) | (unaudited) | ||||||
| Revenue (in thousands): | |||||||
| Product sales | 14,472 | 10,838 | |||||
| Royalty revenue | 26,313 | 35,788 | |||||
| License and other income | 9,000 | -- | |||||
| Total revenue | 49,785 | 46,626 | |||||
Gross Margin was 74% during the first quarter of 2019, as compared to 75% in the first quarter of 2018.
R&D expenses were $6.4 million for the quarter, compared to $17.3 million in the same quarter in the prior year. The first quarter year over year decrease reflects a substantial reduction in fulvestrant expense, partially offset by the cost to bring vasopressin to market. Excluding stock-based compensation and other non-cash and non-recurring items, R&D expense during the first quarter was $5.2 million.
SG&A expenses in the first quarter of 2019 increased to $18.1 million compared to $15.2 million in the first quarter of 2018. External legal expenses associated with litigation on PEMFEXY, vasopressin and bendamustine and higher stock compensation expense account for the year over year increase. Excluding stock-based compensation and other non-cash and non-recurring items, first quarter 2019 SG&A expense was $12.9 million.
Net income for the first quarter of 2019 was $9.0 million, or $0.64 per basic and $0.62 per diluted share, compared to net income of $2.6 million, or $0.18 per basic and $0.17 per diluted share in the three months ended March 31, 2018, due to the factors discussed above.
Adjusted non-GAAP net income for the first quarter of 2019 was $14.6 million, or $1.05 per basic and $1.01 per diluted share, compared to Adjusted non-GAAP net income of $8.2 million or $0.55 per basic and $0.53 per diluted share in the prior year quarter. For a full reconciliation of adjusted non-GAAP net income to the most comparable GAAP financial measures, please see the tables at the end of this press release.
2019 Expense Guidance
- R&D spend in 2019, on a non-GAAP basis, is expected to be $32.0-$36.0 million, as compared to $38.0 million in 2018.
- SG&A spend in 2019, on a non-GAAP basis, is expected to be $51.0-$54.0 million, as compared to $43.0 million in 2018.
The guidance provided in this section represents forward-looking information, and actual results may vary. Please see the risks and assumptions referred to in the Forward-Looking Statements section of this press release.
Liquidity
As of March 31, 2019, the Company had $102.1 million in cash and cash equivalents and $63.9 million in net accounts receivable, $46.6 million of which was due from Teva Pharmaceutical Industries Ltd. The Company had $42.5 million in outstanding debt. Therefore, at March 31, 2019, the Company had net cash and receivables of $123.6 million.
Conference Call
As previously announced, Eagle management will host its first quarter 2019 conference call as follows:
| Date | Tuesday, May 7, 2019 | |||||
| Time | 8:30 A.M. EDT | |||||
| Toll free (U.S.) | 877-876-9176 | |||||
| International | 785-424-1670 | |||||
| Webcast (live and replay) |
www.eagleus.com, under the “Investor + News” section |
A replay of the conference call will be available for one week after the call's completion by dialing 800-839-5493 (US) or 402-220-2552 (International) and entering conference call ID EGRXQ119. The webcast will be archived for 30 days at the aforementioned URL.
About Eagle Pharmaceuticals, Inc.
Eagle is a specialty pharmaceutical company focused on developing and commercializing injectable products that address the shortcomings, as identified by physicians, pharmacists and other stakeholders, of existing commercially successful injectable products. Eagle’s main strategy is to utilize the FDA's 505(b)(2) regulatory pathway. Additional information is available on the Company’s website at www.eagleus.com.
Forward-Looking Statements
This press release contains forward-looking information within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, and other securities laws. Forward-looking statements are statements that are not historical facts. Words and phrases such as “anticipated,” “forward,” “will,” “would,” “may,” “remain,” “potential,” “prepare,” “expected,” “believe,” “plan,” “near future,” “belief,” “guidance,” and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to, statements regarding future events including, but not limited to: the Company’s expense guidance for fiscal year 2019, the Company’s confidence in the remaining products in its pipeline; the Company's ability to deliver value in 2019 and over the long term; the Company’s timing and ability to repurchase additional shares of the Company's common stock, if any, under its share repurchase program; and the Company’s plans and ability to advance the products in its pipeline. All of such statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond Eagle’s control, that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. Such risks include, but are not limited to: whether the Company will incur unforeseen expenses or liabilities or other market factors; whether the FDA will ultimately approve the products in its pipeline for any indications; whether the Company can successfully market and commercialize its product candidates, including RYANODEX, BENDEKA and BELRAPZO, in the treatment of any indications; fluctuations in the trading volume and market price of shares of the Company's common stock, general business and market conditions and management's determination of alternative needs and uses of the Company's cash resources, all of which may affect the Company's long-term performance and the share repurchase program; the success of our commercial relationship with Teva and the parties’ ability to work effectively together; whether Eagle and its commercial partners will successfully perform their respective obligations under their respective agreements; difficulties or delays in manufacturing; the availability and pricing of third party sourced products and materials; the outcome of litigation involving any of our products or that may have an impact on any of our products; successful compliance with the FDA and other governmental regulations applicable to product approvals, manufacturing facilities, products and/or businesses; general economic conditions; the strength and enforceability of our intellectual property rights or the rights of third parties; competition from other pharmaceutical and biotechnology companies and the potential for competition from generic entrants into the market; the timing of product launches; the successful marketing of our products; the risks inherent in the early stages of drug development and in conducting clinical trials; that Eagle’s redirection of resources to other products in its pipeline may not be successful; and other factors that are discussed in Eagle’s filings with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof, and the Company does not undertake any obligation to revise and disseminate forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of or non-occurrence of any events.
Non-GAAP Financial Performance Measures
In addition to financial information prepared in accordance with U.S. GAAP, this press release also contains adjusted non-GAAP net income and adjusted non-GAAP earnings per share attributable to Eagle. The Company believes these measures provide investors and management with supplemental information relating to operating performance and trends that facilitate comparisons between periods and with respect to projected information.
Adjusted non-GAAP net income excludes share-based compensation expense, depreciation, amortization of acquired intangible assets, changes in fair value of contingent consideration, severance, non-cash interest expense, expense of acquired in-process research and development, and tax adjustments. The Company believes these non-GAAP financial measures help indicate underlying trends in the Company’s business and are important in comparing current results with prior period results and understanding projected operating performance. Non-GAAP financial measures provide the Company and its investors with an indication of the Company’s baseline performance before items that are considered by the Company not to be reflective of the Company’s ongoing results. See the attached Reconciliation of GAAP to Adjusted Non-GAAP Net Income and Adjusted Non-GAAP Earnings per Share and Reconciliation of GAAP to Adjusted Non-GAAP EBITDA for explanations of the amounts excluded and included to arrive at adjusted non-GAAP net income, adjusted non-GAAP earnings per share amounts, and adjusted non-GAAP EBITDA amounts, respectively, for the three-months ended March 31, 2019.
These adjusted measures are non-GAAP and should be considered in addition to, but not as a substitute for, the information prepared in accordance with U.S. GAAP. The Company strongly encourages investors to review its consolidated financial statements and publicly-filed reports in their entirety and cautions investors that the non-GAAP measures used by the Company may differ from similar measures used by other companies, even when similar terms are used to identify such measures.
-- Financial tables follow –
| EAGLE PHARMACEUTICALS, INC. | ||||||||||
| CONDENSED CONSOLIDATED BALANCE SHEETS | ||||||||||
| (In thousands, except share amounts) | ||||||||||
| March 31, 2019 | December 31, 2018 | |||||||||
| (unaudited) | ||||||||||
| ASSETS | ||||||||||
| Current assets: | ||||||||||
| Cash and cash equivalents | $ | 102,139 | $ | 78,791 | ||||||
| Accounts receivable, net | 63,930 | 66,486 | ||||||||
| Inventories | 10,265 | 8,304 | ||||||||
| Prepaid expenses and other current assets | 5,895 | 10,263 | ||||||||
| Total current assets | 182,229 | 163,844 | ||||||||
| Property and equipment, net | 2,333 | 2,397 | ||||||||
| Intangible assets, net | 17,473 | 18,103 | ||||||||
| Goodwill | 39,743 | 39,743 | ||||||||
| Deferred tax asset, net | 14,109 | 13,822 | ||||||||
| Other assets | 3,565 | 694 | ||||||||
| Total assets | $ | 259,452 | $ | 238,603 | ||||||
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||||||
| Current liabilities: | ||||||||||
| Accounts payable | $ | 16,786 | $ | 9,917 | ||||||
| Accrued expenses | 22,436 | 23,519 | ||||||||
| Current portion of long-term debt | 5,000 | 6,250 | ||||||||
| Total current liabilities | 44,222 | 39,686 | ||||||||
| Other long-term liabilities | 2,870 | — | ||||||||
| Long-term debt, less current portion | 36,999 | 38,155 | ||||||||
| Commitments and Contingencies | ||||||||||
| Stockholders' equity: | ||||||||||
| Preferred stock, 1,500,000 shares authorized and no shares issued or outstanding as of March 31, 2019 and December 31, 2018 | — | — | ||||||||
| Common stock, $0.001 par value; 50,000,000 shares authorized; 16,519,728 and 16,504,283 shares issued as of March 31, 2019 and December 31, 2018, respectively | 17 | 17 | ||||||||
| Additional paid in capital | 262,084 | 256,458 | ||||||||
| Retained earnings | 67,160 | 58,187 | ||||||||
| Treasury stock, at cost, 2,590,258 and 2,590,258 shares as of March 31, 2019 and December 31, 2018, respectively | (153,900 | ) | (153,900 | ) | ||||||
| Total stockholders' equity | 175,361 | 160,762 | ||||||||
| Total liabilities and stockholders' equity | $ | 259,452 | $ | 238,603 | ||||||
| EAGLE PHARMACEUTICALS, INC. | ||||||||||
| CONDENSED CONSOLIDATED STATEMENTS OF INCOME | ||||||||||
| (In thousands, except share and per share amounts) | ||||||||||
| (unaudited) | ||||||||||
| Three Months Ended March 31, | ||||||||||
| 2019 | 2018 | |||||||||
| Revenue: | ||||||||||
| Product sales | $ | 14,472 | $ | 10,838 | ||||||
| Royalty revenue | 26,313 | 35,788 | ||||||||
| License and other income | 9,000 | — | ||||||||
| Total revenue | 49,785 | 46,626 | ||||||||
| Operating expenses: | ||||||||||
| Cost of product sales | 9,554 | 7,223 | ||||||||
| Cost of royalty revenue | 3,546 | 4,585 | ||||||||
| Research and development | 6,375 | 17,320 | ||||||||
| Selling, general and administrative | 18,141 | 15,193 | ||||||||
| Total operating expenses | 37,616 | 44,321 | ||||||||
| Income from operations | 12,169 | 2,305 | ||||||||
| Interest income | 494 | 27 | ||||||||
| Interest expense | (686 | ) | (675 | ) | ||||||
| Total other expense, net | (192 | ) | (648 | ) | ||||||
| Income before income tax (provision) benefit | 11,977 | 1,657 | ||||||||
| Income tax (provision) benefit | (3,004 | ) | 959 | |||||||
| Net income | $ | 8,973 | $ | 2,616 | ||||||
| Earnings per share attributable to common stockholders: | ||||||||||
| Basic | $ | 0.64 | $ | 0.18 | ||||||
| Diluted | $ | 0.62 | $ | 0.17 | ||||||
| Weighted average number of common shares outstanding: | ||||||||||
| Basic | 13,925,227 | 14,819,530 | ||||||||
| Diluted | 14,418,211 | 15,478,335 | ||||||||
| EAGLE PHARMACEUTICALS, INC. | ||||||||||
| CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS | ||||||||||
| (In thousands) | ||||||||||
| (unaudited) | ||||||||||
| Three Months Ended March 31, | ||||||||||
| 2019 | 2018 | |||||||||
| Cash flows from operating activities: | ||||||||||
| Net income | $ | 8,973 | $ | 2,616 | ||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||
| Deferred income taxes | (287 | ) | (123 | ) | ||||||
| Depreciation expense | 503 | 341 | ||||||||
| Amortization expense | 630 | 670 | ||||||||
| Stock-based compensation expense | 5,782 | 5,305 | ||||||||
| Change in fair value of contingent consideration | — | 27 | ||||||||
| Amortization of debt issuance costs | 94 | 94 | ||||||||
| Changes in operating assets and liabilities which provided (used) cash: | ||||||||||
| Accounts receivable | 2,556 | 395 | ||||||||
| Inventories | (1,961 | ) | (1,023 | ) | ||||||
| Prepaid expenses and other current assets | 4,368 | 1,518 | ||||||||
| Accounts payable | 6,869 | (2,628 | ) | |||||||
| Accrued expenses and other liabilities | (1,083 | ) | (2,289 | ) | ||||||
| Other assets and other long-term liabilities, net | (263 | ) | 18 | |||||||
| Net cash provided by operating activities | 26,181 | 4,921 | ||||||||
| Cash flows from investing activities: | ||||||||||
| Purchase of property and equipment | (177 | ) | (19 | ) | ||||||
| Net cash used in investing activities | (177 | ) | (19 | ) | ||||||
| Cash flows from financing activities: | ||||||||||
| Proceeds from common stock option exercises | 42 | 1,166 | ||||||||
| Payments related to employee net option exercises | — | (3,051 | ) | |||||||
| Employee withholding taxes related to stock-based awards | (198 | ) | — | |||||||
| Payment of contingent consideration | — | (15,001 | ) | |||||||
| Payment of debt | (2,500 | ) | — | |||||||
| Repurchases of common stock | — | (7,003 | ) | |||||||
| Net cash used in financing activities | (2,656 | ) | (23,889 | ) | ||||||
| Net increase (decrease) in cash and cash equivalents | 23,348 | (18,987 | ) | |||||||
| Cash and cash equivalents at beginning of period | 78,791 | 114,657 | ||||||||
| Cash and cash equivalents at end of period | $ | 102,139 | $ | 95,670 | ||||||
| Supplemental disclosures of cash flow information: | ||||||||||
| Cash (received) paid during the period for: | ||||||||||
| Income taxes | $ | (6,490 | ) | $ | 96 | |||||
| Interest | 625 | 368 | ||||||||
| EAGLE PHARMACEUTICALS, INC. | |||||||||||
| RECONCILIATION OF GAAP TO ADJUSTED NON-GAAP NET INCOME AND | |||||||||||
| ADJUSTED NON-GAAP EARNINGS PER SHARE | |||||||||||
| (In thousands, except share and per share amounts) | |||||||||||
| (unaudited) | |||||||||||
| Three Months Ended March 31, | |||||||||||
| 2019 | 2018 | ||||||||||
| Net income - GAAP | $ | 8,973 | $ | 2,616 | |||||||
| Adjustments: | |||||||||||
| Cost of product revenues: | |||||||||||
| Amortization expense | 225 | 265 | |||||||||
| Research and development: | |||||||||||
| Stock-based compensation expense | 1,143 | 1,260 | |||||||||
| Depreciation expense | 69 | 169 | |||||||||
| Expense of acquired in-process research & development | - | 600 | |||||||||
| Severance | - | 255 | |||||||||
| Selling, general and administrative: | |||||||||||
| Stock-based compensation expense | 4,639 | 4,045 | |||||||||
| Amortization expense | 405 | 405 | |||||||||
| Depreciation expense | 172 | 172 | |||||||||
| Other: | |||||||||||
| Non-cash interest expense | 94 | 94 | |||||||||
| Change in fair value of contingent consideration | - | 27 | |||||||||
| Tax effect of the non-GAAP adjustments | (1,091 | ) | (1,727 | ) | |||||||
| Adjusted non-GAAP net income | $ | 14,629 | $ | 8,181 | |||||||
| Adjusted non-GAAP earnings per share: | |||||||||||
| Basic | $ | 1.05 | $ | 0.55 | |||||||
| Diluted | $ | 1.01 | $ | 0.53 | |||||||
| Weighted number of common shares outstanding: | |||||||||||
| Basic | 13,925,227 | 14,819,530 | |||||||||
| Diluted | 14,418,211 | 15,478,335 | |||||||||
| EAGLE PHARMACEUTICALS, INC. | ||||||||||||||||||||
| RECONCILIATION OF GAAP TO ADJUSTED NON-GAAP EBITDA | ||||||||||||||||||||
| (In thousands) | ||||||||||||||||||||
| (unaudited) | ||||||||||||||||||||
|
|
|
|||||||||||||||||||
| Three Months Ended March 31, |
Twelve |
Twelve |
||||||||||||||||||
| 2019 | 2018 | 2019 | 2018 | |||||||||||||||||
| Net income - GAAP | $ | 8,973 | $ | 2,616 | $ | 38,260 | $ | 31,903 | ||||||||||||
| Add back: | ||||||||||||||||||||
| Interest expense, net of interest income | 192 | 648 | 2,123 | 2,579 | ||||||||||||||||
| Income tax provision (benefit) | 3,004 | (959 | ) | 6,098 | 2,135 | |||||||||||||||
| Depreciation and amortization expense | 871 | 1,011 | 3,530 | 3,670 | ||||||||||||||||
| Add back: | ||||||||||||||||||||
| Stock-based compensation expense | 5,782 | 5,305 | 19,559 | 19,082 | ||||||||||||||||
| Change in fair value of contingent consideration | - | 27 | (790 | ) | (763 | ) | ||||||||||||||
| Asset impairment charge | - | - | 2,704 | 2,704 | ||||||||||||||||
| Expense of acquired in-process research & development | - | 600 | 1,100 | 1,700 | ||||||||||||||||
| Severance | - | 255 | 211 | 466 | ||||||||||||||||
| Restructuring charge | - | - | 7,911 | 7,911 | ||||||||||||||||
|
Adjusted non-GAAP EBITDA |
$ | 18,822 | $ | 9,503 | $ | 80,706 | $ | 71,387 | ||||||||||||
